Sammaan Capital: a ₹906 Cr promoter infusion lands at ₹139 a share — above where the stock trades today
Avenir (IHC) paid the balance ₹906 Cr on 8.69 Cr Tranche I warrants on Oct 30, lifting its stake from 28.34% to 33.32%; ₹2,291 Cr more is due by Sep 2027 for 43.28%.
₹137.37 Nov 16, 2026
MID-CAP by market cap ≈ ₹17,191 Cr
33.32%
28.34% before the Oct 30 conversion
₹906 Cr
balance 75% on 8.69 Cr warrants
₹312 Cr
consolidated; ₹243 Cr in Q1
−28.6% high ₹192.34 on Jun 5, 2026
Two filings, a fortnight apart, frame the Sammaan Capital story right now. On October 30, the company allotted 8,68,92,966 equity shares to its promoter, Avenir Investment RSC Ltd — part of Abu Dhabi's International Holding Company (IHC), per the company's investor presentation — on conversion of Tranche I warrants, bringing in the balance consideration of ₹906 crore. On November 14, the Q2 FY27 results showed the book the money is going into: assets under management of ₹59,188 crore, consolidated profit after tax of ₹312 crore, and gross NPA of 0.15%. The conversion came four sessions after the stock touched its 52-week low.
₹906 crore in, stake up to 33.32%
Tranche I warrants converted — 8,68,92,966 shares allotted to Avenir
After market close on October 30, Sammaan Capital intimated the allotment of 8,68,92,966 fully paid-up equity shares of face value ₹2 to Avenir Investment RSC Ltd, the promoter, on conversion of Tranche I warrants. The filing traces the warrants to a preferential issue on a private-placement basis intimated on March 31, 2026, each warrant carrying the right to subscribe to one equity share, with the promoter exercising that right and paying the balance consideration.
Read:The Q2 FY27 earnings presentation puts numbers on the conversion: ₹139 per share, balance 75% consideration of ₹906 crore ($96 million at the presentation's ₹94-per-dollar rate), and the promoter stake moving from 28.34% to 33.32%. The presentation counts the ₹906 crore as received on October 30 — after the September quarter closed — so it sits outside the quarter's reported net worth of ₹19,445 crore.
BSE filing — allotment on conversion of warrants, Oct 30, 2026The price is worth pausing on. The ₹139 conversion price compares with a ₹116.74 close on October 30 — roughly 19% above the market price on the day the money came in, on terms that date from the March 2026 allotment. Avenir's disclosure under Regulation 29(2) of the SEBI (SAST) Regulations followed on November 4, a session in which the stock rose 5.0%; the heaviest-volume session in the last 60, November 5 on 1.58 crore shares, came the day after. The remaining warrants are a stated commitment with a deadline: per the presentation, conversion of the balance 21,97,97,569 Tranche II warrants for ₹2,291 crore — funds receivable in one or more tranches up to the warrant validity of September 30, 2027 — would take the promoter stake to 43.28%.
Warrants priced at ₹139 per share; shares outstanding rise from 1,16,45,56,844 to 1,25,14,49,810 (post Tranche I) and 1,47,12,47,379 (post Tranche II). Tranche II stake assumes no other change in share capital. Source: Q2 FY27 earnings presentation.
The presentation's own book-value bridge shows what the infusion does per share. Net worth of ₹19,445 crore at September 30 becomes ₹20,351 crore with the ₹906 crore added — but spread over 125.14 crore shares instead of 116.46 crore, book value per share moves from ₹167.0 to ₹162.6, and to ₹153.9 on full Tranche II conversion. Converting below book value trims per-share book even as it adds capital; that is the presentation's arithmetic, not a judgment. At ₹137.37, the November 16 close sits below both the post-conversion book value and the ₹139 conversion price.
Sequential growth on a reset base
Q2 FY27: consolidated PAT ₹312 crore, AUM ₹59,188 crore
The board met on Saturday, November 14 and approved the unaudited results for the quarter and half-year ended September 30, 2026. The company's press release headlines disbursements of ₹6,278 crore, up 62% quarter-on-quarter, PAT up 28% quarter-on-quarter, AUM at ₹59,188 crore, and asset quality of 0.15% gross NPA / 0.11% net NPA (from 0.21% / 0.15% in Q1). Capital adequacy stood at 20.0%.
Read:The headline disbursement number was largely pre-announced: an October 5 business update had already flagged approximately ₹6,000 crore of Q2 disbursements and AUM above ₹59,000 crore. That, plus the Saturday filing, left little new for Monday's tape — an inference consistent with the muted first-session move.
Q2 FY27 press release, Nov 14, 2026…scheduled on a Saturday, being a non-trading day, in line with the practice followed by several leading listed entities, including major banks and NBFCs, so as to provide the market with adequate time to assimilate and analyse the financial results before the commencement of the next trading session…
— Board-meeting intimation to BSE, Nov 9, 2026
The sequential story is clean: consolidated PAT of ₹312.34 crore against ₹243.30 crore in Q1, pre-tax profit of ₹424.57 crore against ₹326.01 crore, AUM up 5% quarter-on-quarter. The year-on-year picture is flatter, and belongs in the frame. PAT is 1.3% above Q2 FY26's ₹308.47 crore; pre-tax profit is essentially unchanged (₹425.03 crore a year ago); revenue from operations, at ₹1,849.97 crore, is down 17.8% from ₹2,250.60 crore. The P&L also got help from the impairment line — a net write-back of ₹216.66 crore this quarter and ₹240.47 crore in Q1, versus a ₹229.03 crore charge in Q2 FY26. And the whole recovery sits on a reset base: Q4 FY26 carried a consolidated net loss of ₹8,101.41 crore, which the company attributes to one-time items — a fair-value provision on a change in business model, loss on ARC sale of identified non-core exposures, ECL management-overlay provisions and write-offs of Stage III assets. AUM, at ₹59,188 crore, is growing again but remains below the ₹64,200 crore of Q3 FY26.
Revenue = total revenue from operations. Q4 FY26 includes one-time items per the company (fair-value provision on change in business model, ARC-sale loss, ECL overlay, Stage III write-offs); the company's Q2 FY27 trend charts exclude that quarter, and its AUM is not shown in them. Sources: exchange filings and Q2 FY27 earnings presentation.
Against its own FY27 roadmap, the company is at the halfway mark on some lines and behind on others. Half-year disbursals of ₹10,153 crore compare with a full-year target of ₹30,100 crore; AUM of ₹59,188 crore with a target of ₹70,700 crore; and half-year PAT of ₹556 crore with a target of ₹1,400 crore — which implies roughly ₹844 crore in the second half, against ₹312 crore in Q2 FY27, itself marginally below Q3 FY26's ₹314 crore quarterly PAT. Cost of funds, at 9.8% versus a 9.3% full-year target, comes with the company's own caveat that the target may be revised upwards after the RBI's 25-basis-point repo-rate increase on October 7, 2026. The build-out continues meanwhile: 245 branches (217 at the start of the quarter) against a 270 target, a gold-loan soft launch slated for Q3 FY27, and personal loans scaling from portfolio purchases toward own origination.
From a 52-week low to just under the conversion price
The adjusted series shows the stock touching its 52-week low of ₹111.55 on October 26 — four sessions before the conversion was filed. From the ₹116.74 close of October 30, it has risen 17.7% to ₹137.37 over eleven sessions; the two biggest single-day moves in the series were +6.2% on November 5 and −6.0% on October 19. Even so, the November 16 close is 28.6% below the June 5 high of ₹192.34, and sits just under the ₹139 the promoter paid per share. Whether the gap to book value (₹162.6 post-conversion, per the presentation) narrows is a question the next two quarters of execution will answer, not the tape.
The filings that would change this picture
Tranche II conversion
₹2,291 crore on 21,97,97,569 warrants, receivable in one or more tranches up to Sep 30, 2027. Full conversion takes the promoter stake to 43.28%. Early conversion would be the clearest follow-through signal.
NCLT scheme hearing
The Scheme of Arrangement for the demerger of Sammaan Finserve's NBFC business into Sammaan Capital had its Second Motion Petition admitted on Sep 21, 2026; the NCLT fixed Nov 16, 2026 as the next hearing date.
Board transition
Interim chairman Dinabandhu Mohapatra ceases to be a director from close of business Nov 22, 2026, per the presentation; new independent directors are being appointed as existing ones retire.
H2 FY27 vs targets
The full-year roadmap — PAT ₹1,400 crore, AUM ₹70,700 crore, disbursals ₹30,100 crore — implies a materially heavier second half. Q3 results will show whether the gold-loan launch and branch build-out move the run-rate.
Cost of funds
9.8% now against a 9.3% full-year target the company says may be revised upwards after the Oct 7, 2026 repo-rate increase of 25 bps. The spread between funding cost and the stated 8.5–17% product yield bands drives the PAT target.
The filings establish a specific sequence: a promoter that committed to a warrant programme in March 2026 paid in the second instalment — ₹906 crore at ₹139 a share — in October, at a price well above where the stock was then trading, and has a further ₹2,291 crore due by September 2027. The quarter reported alongside shows sequential growth in disbursements, AUM and profit, with asset-quality ratios of 0.15% gross and 0.11% net NPA and capital adequacy of 20.0%.
The counterweights are equally documented: profit is flat year-on-year on revenue that is down 17.8%, the impairment line is currently a write-back rather than a charge, the recovery base is a Q4 FY26 that absorbed ₹8,101 crore of one-time losses, and book value per share declines as the warrants convert. The data suggests the capital side of the scale-up is being delivered on schedule; whether the earnings side follows is what the FY27 targets — and the next two quarters against them — will test.
Informational and educational content only. Not investment advice.